^
Association details:
Biomarker:IDH1 R132C
Cancer:Cholangiocarcinoma
Drug:Tibsovo (ivosidenib) (IDH1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Excerpt:
...- Have documented IDH1 gene-mutated disease based on local testing procedure (R132C/L/G/H/S mutations variants tested)...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

Excerpt:
...- Have a documented IDH1 R132C, R132L, R132G, R132H, or R132S gene-mutated disease...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

Excerpt:
...Have documented IDH1 gene-mutated disease (from a fresh tumor biopsy or the most recent banked tumor tissue available) based on central laboratory testing (R132C/L/G/H/S mutation variants tested)....
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

426 - Zielgerichtete Therapie eines IDH1-mutierten Cholangiocarcinoms mit Maffucci Syndrom - ein Fallbericht / First report on the targeted therapy of an IDH1-mutated Cholangiocarcinoma in a patient with Maffucci syndrome

Published date:
09/03/2020
Excerpt:
Ivosidenib led to a substantial improvement of patient´s overall physical condition and displayed antitumoral activity and tolerable safety profile in a patient with Maffucci syndrome associated CCa.